Download PDF
Semin intervent Radiol 2024; 41(02): 129-134
DOI: 10.1055/s-0044-1786730
Review Article

Role of Interventional Radiology in Managing Primary and Metastatic Breast Cancer

Amy R. Deipolyi
1   Interventional Radiology, Department of Surgery, WVU/Charleston Area Medical Center, Charleston, West Virginia
,
Robert C. Ward
2   Department of Diagnostic Imaging, The Warren Alpert Medical School of Brown University, Providence, Rhode Island
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Percutaneous image-guided locoregional therapies are emerging in the treatment of primary and metastatic breast cancer. Cryoablation has emerged as the dominant ablative approach as an alternative to surgery for primary breast cancer in patients who do not wish to have surgery or are poor surgical candidates. Cryoablation is well tolerated and provides excellent local control and cosmesis. Thermal ablation may also be used in the treatment of oligometastatic breast cancer, allowing patients to achieve long disease-free intervals. Transarterial therapies have been studied in the treatment of oligoprogressive hepatic metastasis, though further supportive data would be helpful to demonstrate its efficacy.

Keywords

interventional radiology - breast cancer - ablation - embolization - metastasis


Publication History

Article published online:
10 July 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 American Cancer Society. Cancer Facts & Figures 2022. Atlanta, GA: American Cancer Society; 2022
    Google Scholar
  • 2 American Cancer Society. Breast Cancer Facts & Figures 2022–2024. Atlanta, GA: American Cancer Society, Inc.; 2023
    Google Scholar
  • 3 Daye D, Panagides J, Norton L. et al. New frontiers in the role of locoregional therapies in breast cancer: proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel. J Vasc Interv Radiol 2023; 34 (10) 1835-1842
    CrossrefPubMedGoogle Scholar
  • 4 Deipolyi AR, Ward RC, Riaz A. et al. Locoregional therapies for primary and metastatic breast cancer: AJR expert panel narrative review. AJR Am J Roentgenol 2024; 222 (02) e2329454
    CrossrefPubMedGoogle Scholar
  • 5 Ward RC, Lourenco AP, Mainiero MB. Ultrasound-guided breast cancer cryoablation. AJR Am J Roentgenol 2019; 213 (03) 716-722
    CrossrefPubMedGoogle Scholar
  • 6 Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int 2005; 95 (09) 1187-1191
    CrossrefPubMedGoogle Scholar
  • 7 Ward RC, Lourenco AP, Mainiero MB. Implementing breast cryoablation in practice. J Breast Imaging 2020; 2 (01) 61-66
    CrossrefPubMedGoogle Scholar
  • 8 Thai JN, Sevrukov AB, Ward RC, Monticciolo DL. Cryoablation therapy for early-stage breast cancer: evidence and rationale. J Breast Imaging 2023; 5 (06) 646-657
    CrossrefPubMedGoogle Scholar
  • 9 Corines MJ, Sogani J, Hogan MP, Mango VL, Bryce Y. The role of contrast-enhanced mammography after cryoablation of breast cancer. AJR Am J Roentgenol 2024; 222 (02) e2330250
    CrossrefPubMedGoogle Scholar
  • 10 Pigg N, Gordillo C, Wang Y, Ward RC. Breast cancer cryoablation with radiologic-pathologic correlation. Br J Radiol 2022; 95 (1140) 20220480
    CrossrefPubMedGoogle Scholar
  • 11 Roubidoux MA, Sabel MS, Bailey JE, Kleer CG, Klein KA, Helvie MA. Small (< 2.0-cm) breast cancers: mammographic and US findings at US-guided cryoablation–initial experience. Radiology 2004; 233 (03) 857-867
    CrossrefPubMedGoogle Scholar
  • 12 Littrup PJ, Jallad B, Chandiwala-Mody P, D'Agostini M, Adam BA, Bouwman D. Cryotherapy for breast cancer: a feasibility study without excision. J Vasc Interv Radiol 2009; 20 (10) 1329-1341
    CrossrefPubMedGoogle Scholar
  • 13 Habrawi Z, Melkus MW, Khan S. et al. Cryoablation: a promising non-operative therapy for low-risk breast cancer. Am J Surg 2021; 221 (01) 127-133
    CrossrefPubMedGoogle Scholar
  • 14 Manenti G, Perretta T, Gaspari E. et al. Percutaneous local ablation of unifocal subclinical breast cancer: clinical experience and preliminary results of cryotherapy. Eur Radiol 2011; 21 (11) 2344-2353
    CrossrefPubMedGoogle Scholar
  • 15 Pfleiderer SO, Freesmeyer MG, Marx C, Kühne-Heid R, Schneider A, Kaiser WA. Cryotherapy of breast cancer under ultrasound guidance: initial results and limitations. Eur Radiol 2002; 12 (12) 3009-3014
    CrossrefPubMedGoogle Scholar
  • 16 Pfleiderer SO, Marx C, Camara O, Gajda M, Kaiser WA. Ultrasound-guided, percutaneous cryotherapy of small (< or = 15 mm) breast cancers. Invest Radiol 2005; 40 (07) 472-477
    CrossrefPubMedGoogle Scholar
  • 17 Poplack SP, Levine GM, Henry L. et al. A pilot study of ultrasound-guided cryoablation of invasive ductal carcinomas up to 15 mm with MRI follow-up and subsequent surgical resection. AJR Am J Roentgenol 2015; 204 (05) 1100-1108
    CrossrefPubMedGoogle Scholar
  • 18 Sabel MS, Kaufman CS, Whitworth P. et al. Cryoablation of early-stage breast cancer: work-in-progress report of a multi-institutional trial. Ann Surg Oncol 2004; 11 (05) 542-549
    CrossrefPubMedGoogle Scholar
  • 19 Simmons RM, Ballman KV, Cox C. et al; ACOSOG Investigators. A phase II trial exploring the success of cryoablation therapy in the treatment of invasive breast carcinoma: results from ACOSOG (Alliance) Z1072. Ann Surg Oncol 2016; 23 (08) 2438-2445
    CrossrefPubMedGoogle Scholar
  • 20 Fine RE, Gilmore RC, Dietz JR. et al. Cryoablation without excision for low-risk early-stage breast cancer: 3-year interim analysis of ipsilateral breast tumor recurrence in the ICE3 trial. Ann Surg Oncol 2021; 28 (10) 5525-5534
    CrossrefPubMedGoogle Scholar
  • 21 Khan SY, Snitman A, Habrawi Z, Crawford S, Melkus MW, Layeequr Rahman R. The role of cryoablation in breast cancer beyond the oncologic control: COST and breast-Q patient-reported outcomes. Ann Surg Oncol 2023; 30 (02) 1029-1037
    CrossrefPubMedGoogle Scholar
  • 22 Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S179-S186
    CrossrefPubMedGoogle Scholar
  • 23 Roknsharifi S, Wattamwar K, Fishman MDC. et al. Image-guided microinvasive percutaneous treatment of breast lesions: where do we stand?. Radiographics 2021; 41 (04) 945-966
    CrossrefPubMedGoogle Scholar
  • 24 Oura S, Tamaki T, Hirai I. et al. Radiofrequency ablation therapy in patients with breast cancers two centimeters or less in size. Breast Cancer 2007; 14 (01) 48-54
    CrossrefPubMedGoogle Scholar
  • 25 Ito T, Oura S, Nagamine S. et al. Radiofrequency ablation of breast cancer: a retrospective study. Clin Breast Cancer 2018; 18 (04) e495-e500
    CrossrefPubMedGoogle Scholar
  • 26 Roubidoux MA, Yang W, Stafford RJ. Image-guided ablation in breast cancer treatment. Tech Vasc Interv Radiol 2014; 17 (01) 49-54
    CrossrefPubMedGoogle Scholar
  • 27 Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget 2015; 6 (11) 8491-8524
    CrossrefPubMedGoogle Scholar
  • 28 Pagani O, Senkus E, Wood W. et al; ESO-MBC Task Force. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured?. J Natl Cancer Inst 2010; 102 (07) 456-463
    CrossrefPubMedGoogle Scholar
  • 29 Gennari A, André F, Barrios CH. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021; 32 (12) 1475-1495
    CrossrefPubMedGoogle Scholar
  • 30 Bai X-M, Yang W, Zhang ZY. et al. Long-term outcomes and prognostic analysis of percutaneous radiofrequency ablation in liver metastasis from breast cancer. Int J Hyperthermia 2019; 35 (01) 183-193
    CrossrefPubMedGoogle Scholar
  • 31 Jakobs TF, Hoffmann RT, Schrader A. et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 2009; 32 (01) 38-46
    CrossrefPubMedGoogle Scholar
  • 32 Meloni MF, Andreano A, Laeseke PF, Livraghi T, Sironi S, Lee Jr FT. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation–intermediate and long-term survival rates. Radiology 2009; 253 (03) 861-869
    CrossrefPubMedGoogle Scholar
  • 33 Veltri A, Gazzera C, Barrera M. et al. Radiofrequency thermal ablation (RFA) of hepatic metastases (METS) from breast cancer (BC): an adjunctive tool in the multimodal treatment of advanced disease. Radiol Med (Torino) 2014; 119 (05) 327-333
    CrossrefPubMedGoogle Scholar
  • 34 Liu B, Wu Z, Mo H. et al. Safety and efficacy of microwave ablation for breast cancer thoracic metastases. Cancer Manag Res 2018; 10: 5685-5689
    CrossrefPubMedGoogle Scholar
  • 35 Meng M, Han X, Li W. et al. CT-guided microwave ablation in patients with lung metastases from breast cancer. Thorac Cancer 2021; 12 (24) 3380-3386
    CrossrefPubMedGoogle Scholar
  • 36 Ridouani F, Solomon SB, Bryce Y, Bromberg JF, Sofocleous CT, Deipolyi AR. Predictors of progression-free survival and local tumor control after percutaneous thermal ablation of oligometastatic breast cancer: retrospective study. J Vasc Interv Radiol 2020; 31 (08) 1201-1209
    CrossrefPubMedGoogle Scholar
  • 37 Adam R, Aloia T, Krissat J. et al. Is liver resection justified for patients with hepatic metastases from breast cancer?. Ann Surg 2006; 244 (06) 897-907 , discussion 907–908
    CrossrefPubMedGoogle Scholar
  • 38 Bale R, Putzer D, Schullian P. Local treatment of breast cancer liver metastasis. Cancers (Basel) 2019; 11 (09) 1341
    CrossrefPubMedGoogle Scholar
  • 39 Hagemeister Jr FB, Buzdar AU, Luna MA, Blumenschein GR. Causes of death in breast cancer: a clinicopathologic study. Cancer 1980; 46 (01) 162-167
    CrossrefPubMedGoogle Scholar
  • 40 Hoe AL, Royle GT, Taylor I. Breast liver metastases – incidence, diagnosis and outcome. J R Soc Med 1991; 84 (12) 714-716
    CrossrefPubMedGoogle Scholar
  • 41 Beckham TH, Yang TJ, Gomez D, Tsai CJ. Metastasis-directed therapy for oligometastasis and beyond. Br J Cancer 2021; 124 (01) 136-141
    CrossrefPubMedGoogle Scholar
  • 42 Liberchuk AN, Deipolyi AR. Hepatic Metastasis from Breast Cancer. In: Seminars in Interventional Radiology. Thieme Medical Publishers, Inc.; 2020
    Article in Thieme ConnectGoogle Scholar
  • 43 Eichler K, Jakobi S, Gruber-Rouh T, Hammerstingl R, Vogl TJ, Zangos S. Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. Eur J Radiol 2013; 82 (12) e816-e822
    CrossrefPubMedGoogle Scholar
  • 44 Martin RC, Robbins K, Fagés JF. et al. Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat 2012; 132 (02) 753-763
    CrossrefPubMedGoogle Scholar
  • 45 Cianni R, Pelle G, Notarianni E. et al. Radioembolisation with (90)Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol 2013; 23 (01) 182-189
    CrossrefPubMedGoogle Scholar
  • 46 Haug AR, Tiega Donfack BP, Trumm C. et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53 (03) 371-377
    CrossrefPubMedGoogle Scholar
  • 47 Saxena A, Meteling B, Kapoor J. et al. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: a single centre experience of 45 consecutive patients. Int J Surg 2014; 12 (12) 1403-1408
    CrossrefPubMedGoogle Scholar
  • 48 Deipolyi AR, Johnson CB, Riedl CC. et al. Prospective evaluation of immune activation associated with response to radioembolization assessed with PET/CT in women with breast cancer liver metastasis. Radiology 2023; 306 (01) 279-287
    CrossrefPubMedGoogle Scholar
  • 49 Chang J, Charalel R, Noda C. et al. Liver-dominant breast cancer metastasis: a comparative outcomes study of chemoembolization versus radioembolization. Anticancer Res 2018; 38 (05) 3063-3068
    PubMedGoogle Scholar